Fractyl Health, Inc.

Contributing Author

Recent Articles by Fractyl Health, Inc.

12 hours	Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita Procedure GUTS +17.95% GlobeNewswire
Dec-01	Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference GUTS GlobeNewswire
Nov-12	Fractyl Health Reports Third Quarter 2025 Results; Revita Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 GUTS GlobeNewswire
Nov-05	Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 GUTS GlobeNewswire
Oct-07	Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity GUTS GlobeNewswire
Sep-26	Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock GUTS GlobeNewswire
Sep-26	Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita Maintained Weight Loss After GLP-1 Discontinuation GUTS GlobeNewswire
Sep-03	Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth GUTS GlobeNewswire
Aug-12	Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
Aug-07	Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares GUTS GlobeNewswire
Aug-06	Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference GUTS GlobeNewswire
Aug-06	Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering GUTS GlobeNewswire
Aug-05	Fractyl Health Announces Proposed Public Offering GUTS GlobeNewswire
Aug-05	Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure GUTS GlobeNewswire
Jun-23	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy GUTS GlobeNewswire
Jun-23	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models GUTS GlobeNewswire
Jun-18	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing GUTS GlobeNewswire
Jun-13	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions GUTS GlobeNewswire
Jun-04	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide GUTS GlobeNewswire
May-19	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes GUTS GlobeNewswire
May-17	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 GUTS GlobeNewswire
May-13	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates GUTS GlobeNewswire
May-06	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference GUTS GlobeNewswire

Fractyl Health, Inc.

Recent Articles by Fractyl Health, Inc.

Upgrade your FINVIZ experience